公开(公告)号：US20240190890A1

公开(公告)日：2024-06-13

申请号：US18495004

申请日：2023-10-26

Applicant: Bristol-Myers Squibb Company ,  Celgene Corporation

Inventor： Xirui Hu ,  Lixin Qiao ,  Boris Seletsky ,  Matthew Patton ,  Min Cao ,  Farid van der Mei ,  Guobin Miao ,  Ivar McDonald ,  Carolyn Dzierba

IPC: C07D495/14

CPC classification number: C07D495/14

Abstract: The present invention provides compounds, compositions thereof, and methods of using the MK2 inhibitors of the Formula:

公开(公告)号：US20220119388A1

公开(公告)日：2022-04-21

申请号：US17503516

申请日：2021-10-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael C. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US12110290B2

公开(公告)日：2024-10-08

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20240109888A1

公开(公告)日：2024-04-04

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11767322B2

公开(公告)日：2023-09-26

申请号：US17503516

申请日：2021-10-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael C. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20240425505A1

公开(公告)日：2024-12-26

申请号：US18817352

申请日：2024-08-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.